
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) – Research analysts at HC Wainwright lifted their FY2026 EPS estimates for Entrada Therapeutics in a research note issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($3.99) per share for the year, up from their previous forecast of ($4.19). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is ($4.12) per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q4 2026 earnings at ($1.09) EPS, Q1 2027 earnings at ($0.83) EPS, Q2 2027 earnings at ($0.75) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.89) EPS and FY2027 earnings at ($3.29) EPS.
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.07. The firm had revenue of $0.91 million for the quarter, compared to the consensus estimate of $2.30 million. Entrada Therapeutics had a negative return on equity of 64.00% and a negative net margin of 4,057.98%.
Several other analysts also recently weighed in on the company. Roth Capital restated a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. UBS Group reiterated a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th. Wall Street Zen upgraded Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, November 9th. Finally, Weiss Ratings raised Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $17.75.
Check Out Our Latest Stock Report on Entrada Therapeutics
Entrada Therapeutics Price Performance
Entrada Therapeutics stock opened at $5.00 on Monday. Entrada Therapeutics has a 52 week low of $4.11 and a 52 week high of $16.45. The stock has a fifty day moving average of $5.55 and a 200-day moving average of $8.39.
Insider Activity at Entrada Therapeutics
In other news, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $7.41, for a total transaction of $1,426,425.00. Following the completion of the transaction, the insider directly owned 3,913,952 shares in the company, valued at approximately $29,002,384.32. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total transaction of $199,975.88. Following the transaction, the insider owned 4,332,917 shares of the company’s stock, valued at $32,670,194.18. This trade represents a 0.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 495,947 shares of company stock valued at $3,600,470. 9.49% of the stock is owned by insiders.
Institutional Investors Weigh In On Entrada Therapeutics
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Entrada Therapeutics in the second quarter valued at approximately $19,013,000. Nantahala Capital Management LLC bought a new position in Entrada Therapeutics in the 2nd quarter valued at approximately $2,212,232. 5AM Venture Management LLC acquired a new stake in Entrada Therapeutics during the 2nd quarter worth approximately $29,854,949. GSA Capital Partners LLP acquired a new stake in Entrada Therapeutics during the 2nd quarter worth approximately $648,000. Finally, Bank of New York Mellon Corp acquired a new stake in Entrada Therapeutics during the 2nd quarter worth approximately $582,000. Institutional investors and hedge funds own 86.39% of the company’s stock.
Entrada Therapeutics Company Profile
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
Recommended Stories
- Five stocks we like better than Entrada Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
